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Abstract Over the last decade metabolomics has gained
increasing popularity and significance in life sciences.
Together with genomics, transcriptomics and proteomics,
metabolomics provides additional information on specific
reactions occurring in humans, allowing us to understand
some of the metabolic pathways in pathological processes.
Abnormal levels of such metabolites as nucleosides in the
urine of cancer patients (abnormal in relation to the levels
observed in healthy volunteers) seem to be an original
potential diagnostic marker of carcinogenesis. However, the
expectations regarding the diagnostic value of nucleosides
may only be justified once an appropriate analytical
procedure has been applied for their determination. The
achievement of good specificity, sensitivity and reproduc-
ibility of the analysis depends on the right choice of the
phases (e.g. sample pretreatment procedure), the analytical
technique and the bioinformatic approach. Improving the
techniques and methods applied implies greater interest in
exploration of reliable diagnostic markers. This review
covers the last 11 years of determination of urinary
nucleosides conducted with the use of high-performance
liquid chromatography in conjunction with various types of
detection, sample pretreatment methods as well as bio-
informatic data processing procedures.
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Introduction
One of the most unpredictable diseases is cancer, especially
if it is diagnosed in the advanced stage. Many diagnostic
markers have been proposed but none have been proved so
far to be sufficiently sensitive. That is why the mortality
rate due to cancer is still increasing. For instance,
carcinoembryonic antigen (CEA), carbohydrate antigen
(CA) 199, CA 125 and α-fetoprotein (AFP) were demon-
strated to have insufficient sensitivity for testing for cancer
and are currently used solely to detect a single type of the
disease [1–3]. Moreover, the commonly available diagnostic
tests, such as the test for prostate-specific antigen, can yield
false-negative results.
Unlike the biochemical diagnostic approach, which
focuses on single markers, metabolomics takes into account
larger groups of metabolites and is therefore expected to
limit the likelihood of false-negative results. In addition, it
seems that a holistic approach (involving the analysis of
metabolite profiles as a reflection of the individual’s health
status) can provide a more reliable answer as to the
presence or absence of cancer.
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Nucleoside levels measured in urine samples may play a
significant role as possible tumour markers. The justifica-
tion of this hypothesis refers to a fundamental metabolic
process, namely RNA turnover. In such pathological
processes as blood disorders, inflammation, AIDS and
malignancies, degradation of RNA is more rapid. The
subsequent correlation between the presence of cancer and
nucleoside levels might be due to the increased methyl-
transferase activity. As a result of both processes (increased
RNA turnover and increased enzymatic activity), normal
nucleosides undergo reutilisation and degradation to uric
acid (as in the case of adenosine and guanosine), β-alanine
(as in the case of cytidine and uridine) and β-
aminoisobutyrate [4, 5]. Modified nucleosides, on the other
hand, are not degraded or reutilised. Instead, they undergo
distribution to the bloodstream and subsequent elimination
with the urine in the unchanged form. Their abnormal
urinary levels therefore correlate with either increased RNA
turnover or increased methyltransferase activity, both of
which are caused by cancer. This conclusion is not,
however, clear and definitive. It cannot be presumed that
patients with a more rapid RNA degradation have cancer or
are at high risk of having cancer. They could be suffering
from other disorders associated with increased cell turn-
over, such as chronic hepatitis and liver cirrhosis [6]. In
terms of cancer these patients are initially considered
healthy, but after some of the common tumour markers (e.g.
AFP, CEA, CA 199 or CA 125) have been determined, they
are reclassified as cancer patients. This may lead to false-
positive results. One way of limiting such an undesirable
situation is to use highly specific and sensitive biomarkers and
to carefully select non-cancer volunteers. According to the
literature, urinary nucleosides seem to be more specific and
selective than the tumour markers commonly employed so far.
A large number of papers have emphasised that urinary
nucleosides, especially modified ones, may be used as a
diagnostic tool in various cancers, e.g. leukaemia [7],
lymphoma [8], nasopharyngeal cancer, breast cancer
[9–11], colorectal cancer [12, 13], bronchogenic carcinoma
[14], bladder cancer [15–18] and hepatocellular carcinoma
[6]. The fact that nucleoside levels do not depend on age
and sex [5] suggests that these variables do not need to be
taken into account when developing relevant diagnostic
tests. On the other hand, nucleoside levels are also elevated
in some physiological states, such as intensive body growth
and pregnancy. All in all, it is important to emphasise that
clinical use of nucleosides in the diagnosis of cancer is still
confirmatory in nature and the results obtained from
adequate analysis should be supported by the already
available and widely used diagnostic methods, such as
ultrasonography, cytology, histopathology and radiography.
The increased interest in metabolomics and the signifi-
cant correlation between nucleosides and the processes
implied by the presence of cancer have generated increas-
ing interest in analytical and bioinformatic techniques
involving these agents. Nucleosides can be analysed using
various techniques according to their physicochemical
properties, such as hydrophilic structure, molecular mass,
electric charge over a wide pH range and ability to absorb
both visible and UV light. The first paper on determination
of urinary nucleosides, by Gehrke et al. [19], was published
in 1978. The authors successfully determined six nucleo-
sides in urine samples from healthy individuals and cancer
patients using affinity liquid chromatography (LC) with a
bound boronic acid stationary phase. Since that time,
various techniques have been developed and applied to
achieve greater sensitivity not only in chromatographic but
also in electromigration methods. In this paper we review
chromatographic determinations of the urinary nucleosides
focusing particularly on papers published in the past
11 years.
Sample pretreatment procedure
Offline extraction
The sample pretreatment procedure is often the most
important step in the entire analysis. The adaptation of an
appropriate selective pretreatment method for analytes
usually protects the matrix purification process from
interferences.
To obtain well-purified and concentrated samples, the
physicochemical properties and structures of the analytes
need to be taken into account [20]. Numerous methods
have been tested for satisfactory purification of nucleosides
from the complex matrix of such biological samples as
urine, serum, blood and even tissues. Nowadays, solid-
phase extraction is often regarded as the best method. Boos
et al. [21], for instance, proposed phenylboronic acid as an
extraction agent for nucleosides because of its unique
properties. This phase is selective for nucleosides thanks to
the vicinal hydroxyl groups in their structure (during
extraction the vicinal groups of nucleosides bind to the
phenylboronic acid phase under basic conditions). While
preserving basic conditions, one can purify samples from
interferences without any loss of analytes. Only the
alteration of pH from basic to acidic offers the chance to
release analytes from the extraction phase and for them to
be eluted afterwards. Thanks to that, the extracted and
eluted analytes can be analysed further.
Many various modifications of phenylboronic acid as the
extraction phase have been proposed over the years.
Therefore, more and more reports are continuing to reveal
that the phenylboronic acid phase is the method of choice
for extraction of nucleosides. It should, however, be
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recognised that in the case of mixtures containing nucleo-
sides without cis-diol groups, phenylboronic acid as the
extraction phase does not play a significant role. In this
case, other extraction phases, such as cation-exchange
columns, are more suitable. Hsu et al. [22] proposed a
cation-exchange MCX column with sulfate functional
groups for nucleoside determination. This column is
appropriate for all acidified nitrogen-containing nucleo-
sides. Therefore, with this column it is possible to extract
the deoxynucleosides which do not have vicinal groups in
their structure, e.g. 2′-deoxyguanosine and 8-hydroxy-2′-
deoxyguanosine [10, 22–26]. These two nucleosides are
considered markers of oxidative DNA damage, which is
also related to carcinogenesis.
Solid-phase extraction with C18 columns can also be
applied for deoxynucleoside determination [7]. Moreover,
according to a recent report [27], solid-phase microextraction
seems to be a very promising method as far as nucleoside
extraction is concerned. The method proposed by He et al.
[27] relies on the high affinity of phenylboronic acid for
these agents. The authors [27] used poly(3-aminophenylbor-
onic acid) as the extraction material; this can selectively
capture analytes with 1,2 or 1,3 cis-diol groups under basic
conditions. A change of the pH from basic to acidic results
in the previously captured analytes being subsequently
released from the extraction phase and then eluted.
Online extraction
Sample pretreatment is usually considered a separate
procedure to be carried out by the analyst. However,
modern analytical techniques make it possible to automate
it by integration within analytical equipment. The extraction is
then performed online.
Hagemeier et al. [28] applied a method in which the
standard extraction procedure was omitted and phenylboronic
acid was substituted for the silica column in the process. The
proposed analytical procedure was fully automated and based
on using two coupled columns: a phenylboronic acid
substituted silica column to clean and concentrate the analytes
derived from the biological matrix, and a second column to
perform the analytical chromatographic separation.
This approach has many advantages. For instance, the
total analysis time is much shorter and the risk of specimen
contamination or loss of analytes is limited. Following the
example of Hagemeier et al. [28], more and more reports
have suggested the use of a phenylboronic acid column
directly connected to an analytical chromatographic one
[2, 12, 29, 30].
The method developed by Cho et al. [25, 31] also did not
require any separate pretreatment procedure. The authors
efficiently removed interferences from the matrix using
column-switching LC. Instead of a phenylboronic acid
substituted silica column, they used an n-vinylacetamide
copolymer column to clean the samples.
Instead of a phenylboronic acid column, Kowalska et al.
[32] proposed a different column. They presented three
different laboratory-made columns that may be useful for
the analysis of nucleosides with competitive results.
Procedure without extraction
Although extraction seems to be the method of choice in the
analysis of nucleosides, there are some applications that omit
this step. Hewavitharana and Bruce [23] determined two
analytes, creatinine and pseudouridine, without using any
extraction methods before the chromatographic analysis. They
analysed bovine blood treated with acetone and then mixed
and centrifuged. To concentrate the analytes, the supernatant
was evaporated and the residue was subsequently dissolved in
an appropriate solvent directly before the analysis.
Another interesting approach has been proposed by Lee
at al. [33], who developed an LC/electrospray ionisation
(ESI) mass spectrometry (MS) method for urinary nucleo-
sides, also without extraction. They showed that the
analysis of nucleosides using the positive-ion mode with
selected reaction monitoring effectively eliminated interfer-
ences from the endogenous constituents of the urine. This
approach was both more convenient and more efficient in
analysing large numbers of samples compared with the
analytical methods involving complex extraction and/or
derivatisation steps, as is the case with gas chromatography
(GC) techniques [34].
Non-chromatographic techniques
Non-chromatographic methods are rarely used for the
determination of nucleosides in biological samples. Some
papers have reported on the use of immunoassays. Enzyme
immunoassay used for the determination of normal and
modified nucleosides is based on a specific complex
reaction between the analyte and its unique antibody that
is determined afterwards. This technique is considered
specific and sensitive. However, it is not widely used
because of limited applicability. So far it has only been
performed for six nucleosides, for which specific antibodies
have been developed: 5-methylcytidine, N4-acetylcytidine
1-methylinosine, 1-methyladenosine, 7- methylguanosine
and pseudouridine [8, 9, 35].
Chromatographic techniques
Nowadays, chromatographic techniques are well-
established and commonly used in the analysis of nucleo-
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sides. Thanks to their structure, nucleosides can be
determined by various types of detection, e.g. photometric,
electrochemical and MS. In addition, according to the latest
literature reports, the ultraperformance LC (UPLC) tech-
nique and the hydrophilic interaction chromatography
(HILIC; also called “reverse reversed-phase” or “aqueous
normal phase” chromatography) method with various
modifications seem to be a good alternative for standard
nucleoside analysis [24, 29].
The reported chromatographic methods for the determi-
nation of nucleosides are summarised in Tables 1 and S1
and a typical chromatogram of a nucleoside profile is
presented in Fig. 1.
As presented in Tables 1 and S1, urinary nucleosides can
be determined not only by high-performance LC (HPLC)
and UPLC, but also by GC. However, in this case a very
time consuming pretreatment procedure, which usually
involves a hydrolytic reaction and/or a derivatisation step,
renders this method rarely employed [34, 36].
Owing to their physiochemical properties, nucleosides
are mainly analysed by reversed-phase HPLC with a C18
column. In this method, the mobile phase usually contains
an appropriate buffer and an organic modifier: acetonitrile
or methanol in various proportions (Table S2).
A good modern method of determination of nucleosides
is UPLC. UPLC, which employs a column packed with 1.7-
Table 1 Examples of modifications of chromatographic methods used for determination of nucleosides in biological samples. All available
methods are presented in Table S1
No. of nucleosides Detection type Analytical conditions Aplications References
14 UV at 260 and 280 nm Offline solid-phase extraction with phenylboronic acid gel Urine [1]
Analytical column: LiChrospher 100 C18 column
(250 mm×4 mm, 5 μm) at 22 °C
9 LC/MS/MS with positive
ionisation
Offline solid-phase extraction using a cation-exchange
cartridge with sulfate functional groups
Urine [22]
Analytical column: Atlantis dC18 (2.1 mm×100 mm, 5 μm)
with a guard column (Atlantis dC18, 2.1 mm×20 mm, 5 μm)
Not given MS detection in positive ion
mode as well as UV
detection at 260 nm
Offline solid-phase extraction with phenylboronic
acid gel
Urine [24]
UPLC column: ACQUITY C18 column
(100 mm×2.1 mm, 1.7 μm)
HPLC column: Symmetry C18 column
(150 mm×2.1 mm, 3.5 μm)
13 LC/MS/MS Online extraction with a Shodex MS Pak PK-2A column
(n-vinylacetamide copolymer, 2.0 mm×10 mm)
Urine [25]
Analytical column: Capcell Pak C18-AQ
(1.5 mm×150 mm, 5 μm)
3 UV at 260 nm and QTRAP MS
in positive ionisation mode
Online extraction using an aprotic boronic acid precolumn Urine [29]
Analytical column: poly(hydroxyethyl aspartamide)
HILIC column (15 cm×300 μm i.d.)
13 ESI-MS with positive mode Sample pretreatment shortened only to the filtration step.
No extraction procedures were performed
Urine [33]
Analytical column: Atlantis C18 column
(150 mm×2.1 mm, 5 μm)
14-16 MS in positive ion mode Three methods were proposed: GC/MS, HPLC/IT-MS
and CapLC/TQMS
Urine [36]
GC/MS: long pretreatment procedure consisted of
deproteinisation, partial purification by C18,
phenylboronate chromatography and derivatisation.
Separation was performed using a DB-5 capillary
column (30 m×0.25 m, 025 μm)
HPLC/IT-MS column: Spherisorb ODS 5 μm C18
HPLC column (150 mm×4.6 mm)
CapLC/TQMS: Hypersil C18 BDS column
(15 cm×300 μm) and a mobile phase containing
0.05 M ammonium formate pH 3.5 and methanol
CapLC capillary liquid chromatography, ESI electrospray ionisation, GC gas chromatography, HILIC hydrophilic interaction chromatography,
HPLC high-performance liquid chromatography, i.d. inner diameter, IT ion trap, LC liquid chromatography, MS mass spectrometry, TQMS triple
quadrupole mass spectrometry, UPLC ultraperformance liquid chromatography
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μm porous particles, seems to be more efficient than HPLC.
The size of the particles provides a higher peak capacity,
greater resolution and increased sensitivity. Zhao et al. [24]
determined nucleosides by UPLC and HPLC with UV and
MS detection. To compare HPLC and UPLC, the authors
performed an analysis under identical conditions (Tables 1,
S1, S2). As a result, 79 peaks were found in the case of
HPLC-UV detection and 92 in case of UPLC-UV detection.
UPLC yielded more peaks of high-performance efficiency.
Regarding MS, it was possible to detect 11,000 ions
(UPLC) and 8,000 ions (HPLC). The authors [24] also
proved that the UPLC needed about one third of the time
required by HPLC, while achieving a much better resolu-
tion and supplying more comprehensive information on
metabolites.
Henriksen et al. [26] also used the UPLC-MS technique.
They focused on the two nucleosides from urine samples,
namely 8-oxoguanosine and 8-oxo-2′-deoxyguanosine,
which play a pivotal role in oxidative DNA damage. The
authors proposed a rapid (23 min) and automated method
which can be useful for large-scale studies. The quantifica-
tion limit in urine samples was 1 nM for both analytes. In
addition, accuracy and precision were documented, show-
ing average recoveries of 106.2% (8-oxoguanosine) and
106.9% (8-oxo-2′-deoxyguanosine), and the overall within-
day and between-day precision was 6.1% and 4.4%,
respectively.
The HILIC method is also worth considering. Its
characteristic feature is the use of a polar stationary phase
(e.g. silica, cyano) and a highly organic mobile phase (95–
65% acetonitrile) with a smaller amount of aqueous solvent.
In contrast to the composition of the mobile phase widely
used in reversed-phase HPLC (Table S2), the aqueous
solvent in HILIC is classified as a stronger eluent than the
organic modifier. Therefore, this method can retain highly
polar analytes that would not be retained by reversed-phase
chromatography. Moreover, it shows a complementary
selectivity for the reversed phase and shortens the sample
preparation procedure: it makes it possible to omit the
evaporation step following the usually performed extraction
because the organic extract may be directly injected into the
organic eluent.
Tuytten et al. [29] proposed a new approach using a
HILIC column. They developed a method with an aprotic
boronic acid precolumn, which was switched to the HILIC
column: polyhydroxyethyl aspartamide. The mobile phase
for the precolumn was 100% acetonitrile. Regarding the
HILIC column, there were two eluents: eluent A was
10 mM ammonium formate in 95:4.8:0.2 acetonitrile/water/
formic acid and eluent B was 10 mM ammonium formate in
50:49.8:0.2 acetonitrile/water/formic acid. The process was
fully automated and allowed determination of three nucleo-
sides in 40 min. Thanks to the aprotic boronic acid
precolumn, the typical extraction procedure was eliminated
and the analytes were well-purified and concentrated.
However, this method can be adapted only for determina-
tion of nucleosides that are very soluble in acetonitrile,
otherwise the high amount of acetonitrile in the initial
mobile phase can cause precipitation of the analytes. It is
also important to remember that every analyte determined
with the use of the HILIC column should be dissolved in
the solvent that is “weaker” than the initial mobile phase
(or, in the worst case, in the initial mobile phase itself).
Although the HILIC method is designed for polar
analytes that are not retained on the reversed-phase HPLC
column, it is also appropriate for analytes soluble in high
amounts of acetonitrile. That is why the physicochemical
properties of the analytes and the sample origin (e.g. urine,
blood) are pivotal factors taken into account in the selection
of the HILIC method.
Fig. 1 Chromatographic metabolite profiling analysis of a nucleoside
standard mixture and b nucleosides extracted from urine. 1 pseudour-
idine, 2 cytidine, 3 uridine, 4 1-methyladenosine, 5 inosine, 6 5-
methyluridine, 7 guanosine, 8 1-methylinosine, 9 1-methylguanosine,
10 N4-acetylcytidine, 11 N2-methylguanosine, 12 adenosine, 13 N2,N2-
dimethylguanosine, 14 internal standard (8-bromoguanosine), 15 6-
methyladenosine. (With permission from [12])
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A different approach was proposed by Dudley et al. [36].
They compared three techniques: GC/MS, HPLC/ion trap
MS (IT-MS) and capillary LC triple quadrupole MS
(CapLC/TQMS) with either a full or a controlled neutral
loss scan. All these methods proved to be valuable
techniques for the analysis of urinary nucleosides.
In the case of GC/MS, the derivatisation step was
required, which significantly prolonged the total analysis
time. However, thanks to the derivatisation step, dihydrour-
idine and 3-methylcytidine could be determined, whereas in
the case of the LC techniques neither was detected.
Moreover, each method detected two singly methylated
guanosines and one dimethylguanosine, whereas the two
LC/MS methods detected another analyte, namely a
trimethylated guanosine. Similarly to GC/MS, CapLC/
TQMS was also very time consuming because of the long
reequilibration time (1 h) in comparison with HPLC
(15 min).
Dudley et al. [36] compared the sensitivity of the
methods, and GS/MS was shown to be tenfold less
sensitive than HPLC/IT-MS in the analysis of nucleosides.
CapLC/TQMS with the full scan mode, in turn, offered a
vast improvement in sensitivity. The sensitivity was still
better than that of HPLC/IT-MS when constant neutral loss
mode of scanning was applied, although the difference in
sensitivity between full and constant neutral loss modes
was very significant. It is important to note that the authors
proposed applying each method instead of choosing only
one because the methods used together provide valuable
information.
Type of detection
Up to now, most of the methods have been based on UV
spectrophotometric detection with a wavelength usually set
at 254 nm [1, 2, 7, 10, 12, 13, 23, 37–43]. However, this
detection method is not completely satisfactory as, for
instance, dihydrouridine absorbs light at 210 nm [44]. To
overcome this problem a diode-array detector, which allows
measurements over the full range of the UV spectrum, can
be applied.
An interesting approach was proposed by Kelly et al.
[45]. They determined products of oxidative stress using
HPLC coupled with both UV and electrochemical detec-
tion. Electrochemical detection allows for a specific
determination of oxidation products, 8-oxoguanosine and
8-hydroxydeoxyguanosine, which is not possible with
simple UV detection. However, UV detection allows for
simultaneous detection of unmodified products. The advan-
tages of the proposed method were the short time of analysis
and good resolution. Hence, it can be used as an alternative
approach for determination of urinary nucleosides, especially
those which reflect oxidative DNA damage.
It is worth noting that spectrophotometric detection is
not very sensitive, especially when nucleosides are deter-
mined in biological samples. It is also well known that to
confirm the identity of each nucleoside reference standards
are required. Unfortunately, only several of them are
commercially available. Hence, this type of detection is
not satisfactory because of both poor selectivity and poor
detection limits. To improve the sensitivity and determine
all the desired nucleosides in urine samples, MS detection
should be employed.
HPLC/MS analysis has several advantages over the
previously discussed detection methods. The coupling of
HPLC instrumentation to a mass spectrometer facilitates
further identification of the nucleoside by identifying the
nucleoside’s quasi-molecular ion, thereby allowing mass
determination, and by MS/MS fragmentation, providing
structural information about the nucleoside. HPLC/MS also
allows quantitation of more than one nucleoside at a time,
unlike some of the methods applied earlier, such as
immunoassay [35].
As far as determination of urinary nucleosides is
concerned, MS is very often used with great success. In
most reports, ESI in positive mode has been described
[22, 24–26, 31, 33, 34, 46]. Dudley et al. [47] checked both
negative and positive ionisation modes. The intensity was
far greater in the positive than in the negative ionisation
mode.
Bullinger et al. [48] focused on a different approach
from those described in the other reports. The isolated
metabolites were analysed by IT-MS and Fourier transform
ion cyclotron resonance MS. As a result, the authors
identified 22 metabolites deriving from cellular RNA
metabolism and related metabolic pathways, among which
four modified nucleosides were found for the first time,
namely 2-methylthio-N6-(cis-hydroxyisopentenyl)-adeno-
sine, 5-methoxycarbonylmethyl-2-thiouridine, N6-methyl-
N6-threonylcarbamoyladenosine and 2-methylthio-N6-
threonylcarbamoyladenosine.
Kammerer et al. [49] developed an auto-LC/MS3
method. Whereas the MS/MS spectra only show the nucleic
base fragment, the MS3 fragmentation step provides further,
valuable information about the structure of the nucleic base
itself. Therefore, the authors were able to identify 15
nucleosides by their retention times and three by comparing
the fragmentation with that of standard substances.
Kammerer et al. [42] used matrix-assisted laser desorption/
ionisation (MALDI) time-of-flight MS with a 337-nm
nitrogen laser to identify nucleosides. As the matrix
substances, 2,5-dihydroxybenzoic acid and α-cyano-4-
hydroxycinamic acid (CHCA) were used. Postsource decay
(PSD) spectra of the molecular ions were also recorded. The
PSD spectra of the nucleosides showed a characteristic
cleavage between the sugar moiety and the nucleic base.
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Depending on the basicity of the nucleoside, using CHCA as
the matrix, the detection limit ranged from 100 fmol to
10 pmol.
Apart from good sensitivity, there is also a disadvantage
of using this method. MALDI is an offline technique with
increased sample preparation requirements: sample prepa-
ration for MALDI analysis is quite a time-consuming
procedure.
Chemometric processing of nucleoside separation data
The large data sets obtained after each analysis contain not
only chemical results but also inexplicit information about
patients, for instance, sex, age, health and disease status.
Therefore, it appears advisable to take into account every
kind of data available, whether straightforward or hidden in
multidimensional data sets.
To correlate analytical data with the physiological or
pathophysiological status of the donor of the analysed
biological material, a simple mathematical procedure cannot
suffice. However, thanks to the advanced bioinformatic
methods which can cope with vast data sets, it is possible to
extract systematic information originally dispersed over
extensive data matrices. Over the last decade, the bioinfor-
matic approach has been improved and some previously
unresolved technical problems are nowadays simple and easy
to handle.
In regard to urinary nucleosides, the most important
challenge is the confirmation that nucleosides can serve
as universal markers in urogenital cancer. In some forms
of cancer it is speculated that nucleosides are potential
disease markers. For instance, pseudouridine is a far-
sighted factor in colorectal cancer. Other nucleosides,
such as 1-methyladenosine, 5-hydroxymethyl-2′-deoxy-
uridine and 8-hydroxy-2-deoxyguanosine, may play the
role of biomarkers in breast cancer patients.
Zheng et al. [2] verified the hypothesis of significant
differences in the levels of nucleosides in various stages of
cancer. They [2] determined 14 nucleosides derived from
urine samples obtained from (1) colorectal cancer patients,
(2) patients with intestinal villous adenoma and (3) healthy
adults. When the mean values for the three groups were
analysed, the most abundant nucleoside appeared to be
pseudouridine, followed by 1-methyladenosine and 1-
methylinosine. The pseudouridine level was elevated above
the normal values plus two standard deviations in 58%
(30/52) of patients with colorectal cancer, whereas in 20%
(2/10) of patients with intestinal villous adenoma it was just
elevated. It was also found that the level of these nucleo-
sides positively correlated with the tumour size and Duke’s
stage of colorectal cancer (p<0.05). However, no signifi-
cant correlations were noticed for the observed values with
regard to tumour differentiation. The concentrations of 12
nucleosides (except uridine and guanosine) were signifi-
cantly elevated in patients with colorectal cancer (p<0.05)
(Tables 2, 3).
The second aim of the study by Zheng et al. [2] was to
verify whether there were significant changes in the
concentrations of nucleosides before and after surgery.
The patients were classified into two groups: the response
group (32 patients) and the progressive disease group (11
patients). Using the paired t test, the concentrations of such
nucleosides as pseudouridine, 1-methyladenosine, 1-
methylinosine, 1-methylguanosine, N-4-acetylocytidine
and dimethylguanosine from the response group before
surgery were significantly higher than those of patients after
surgery (p<0.05). However, the presurgery and postsurgery
difference in the levels of these nucleosides for the
progressive disease group showed no significant changes.
Zheng et al. [2] also compared the sensitivity of urinary
nucleosides in patients with colorectal cancer with the
sensitivity of the commonly used tumour markers, such as
CEA. Using concentrations of 14 nucleosides as the data
vectors for principal component analysis (PCA), they
distinguished 71% (37/52) of the patients with colorectal
cancer from healthy adults, whereas healthy adults were
correctly classified at 96% (58/60) specificity (Fig. 2).
Taking into account the specificity of the CEA method,
which was 29% (15/52), it seems highly probable that
nucleosides may play an important role as a predictive tool
in carcinogenesis.
In parallel with the above report, Feng et al. [1]
confirmed a significant biomarker role of urinary nucleo-
sides in patients with colorectal cancer. When the PCA
method was used, higher levels of 11 out of 14 nucleosides
were demonstrated in cancer patients compared with
healthy individuals. In addition to the concentration of 1-
methyladenosine, the concentrations of pseudouridine and
1-methylguanosine were much higher in patients with
colorectal cancer and may also be promising as diagnostic
tools soon (Table 2, 3). The results were compared with the
commonly used tumour markers, such as CEA, CA 199,
CA 125 and AFP. The sensitivity of the analysis was much
higher (76.9%) than that of CEA (38.5%), CA 199 (40.4%),
CA 125 (15.4%) and AFP (17.3%). These results confirm
that the value of urinary nucleosides has already been
appreciated.
The first report on using HPLC/ESI-MS/MS in the analysis
of nucleosides in urine samples from patients with colorectal
cancer was by Hsu et al. [22]. They determined nine
nucleosides (cytidine, 3-methylcytidine, 1-methyladenosine,
uridine, adenosine, inosine, 2-deoxyguanosine, 8-hydroxy-
2′-deoxyguanosine and N,N-dimethylguanine) in urine sam-
ples from cancer patients and healthy volunteers. The
selected reaction monitoring mode was used in this study
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and therefore made it more specific and sensitive for
quantitative analysis (Fig. 3). To increase the reliability of
the data, each corrected mean concentration of the nucleo-
sides in the cancer group was converted to a percentage of
the corresponding normal mean value. In the reviewed study,
the ttest and Pearson’s test were used to measure the
differences between cancer patients and the healthy controls
(p<0.05). It was showed that five urinary nucleosides may
play a pivotal role in colorectal cancer, namely cytidine,
adenosine, 8-hydroxy-2′-deoxyguanosine, N,N-dimethylgua-
Table 2 Mean urinary nucleoside concentrations (μmol nucleoside/mM creatinine) in urine of non-cancer controls
Chromatographic methods
Compound/sample Feng et al. [1];
n=62
Zheng et al. [2];
n=60
Seidel et al. [13];
n=41
Cho et al. [25];
n=150
Cho et al. [31];
n=30
Pseudouridine 22.74 (±6.86) 22.08 (±5.11) 52.20 (±5.53) 13.72 (±7.53) 13.28 (± 7.31)
Uridine 0.29 (±0.18) 0.30 (±0.15) 7.22 (±2.45) 0.18 (±0.11) 0.20 (±0.11)
5-Methyluridine 0.01 (±0.07) 0.04 (±0.06) 4.73 (±1.04) – –
Cytidine 0.14 (±0.14) 0.15 (±0.12) 26.12 (±6.45) 0.12 (±0.08) 0.11 (±0.07)
N4-Acetylcytidine 0.66 (±0.23) 0.69 (±0.20) – – –
Inosine 0.29 (±0.27) 0.28 (±0.11) 6.83 (±1.41) – –
Guanosine 0.09 (±0.04) 0.09 (±0.03) – 0.07 (±0.04) 0.07 (±0.04)
N2,N2-Dimethylguanosine 1.23 (±0.37) 1.25 (±0.23) 0.56 (±0.15) 0.29 (±0.17) 0.34 (±0.17)
Xanthosine – – 27.38 (±11.12) – –
Adenosine 0.51 (±0.20) 0.52 (±0.16) 6.56 (±1.26) 0.21 (±0.30) 0.23 (±0.13)
1-Methyladenosine 2.03 (±0.70) 2.04 (±0.53) 7.49 (±1.21) 1.66 (±0.98) 1.62 (±0.91)
6-Methyladenosine 0.03 (±0.03) 0.04 (±0.02) 0.89 (±0.28) – –
1-Methyloinosine 1.19 (±0.37) 1.25 (±0.28) 5.22 (±0.62) – –
1-Methylguanosine 0.79 (±0.29) 0.82 (±0.24) 1.81 (±0.25) – –
2-Methylguanosine 0.55 (±0.19) 0.55 (±0.14) 2.28 (±0.30) – –
n number of samples tested
Table 3 Mean urinary nucleoside concentrations (μmol nucleoside/mM creatinine) in urine of cancer patients
Chromatographic methods
Compound/sample Feng et al. [1];
n=52
Zheng et al. [2];
n=52
Seidel et al. [13];
n=68
Cho et al. [25];
n=150
Cho et al. [31];
n=30
Pseudouridine 39.63 (±31.09) 42.19 (±22.25) 79.73 (±4.75) 11.14 (±7.02) 18.17 (± 11.56)
Uridine 0.25 (±0.20) 0.31 (±0.23) 9.96 (±2.29) 0.20 (±0.10) 0.20 (±0.12)
5-Methyluridine 0.11 (±0.09) 0.13 (±0.08) 6.83 (±1.45) – –
Cytidine 0.3 (±0.25) 0.43 (±0.49) 141.64 (±14.52) 0.13 (±0.13) 0.11 (±0.08)
N4-Acetylcytidine 0.85 (±0.41) 0.84 (±0.30) – – –
Inosine 0.43 (±0.27) 0.50 (±0.35) 5.56 (±1.07) – –
Guanosine 0.08 (±0.06) 0.10 (±0.04) – 0.10 (±0.13) 0.09 (±0.10)
N2,N2-Dimethylguanosine 1.71 (±0.77) 1.81 (±0.55) 3.96 (±1.14) 0.55 (±0.22) 0.49 (±0.17)
Xanthosine – – 22.52 (±8.27) – –
Adenosine 0.66 (±0.72) 0.66(±0.30) 10.59 (±3.94) 0.27 (±0.37) 0.24 (±0.20)
1-Methyladenosine 2.76 (±1.18) 2.74 (±0.80) 15.54 (±2.99) 2.83 (±1.59) 2.54 (±1.41)
6-Methyladenosine 0.04 (±0.07) 0.07 (±0.05) 1.54 (±0.30) – –
1-Methyloinosine 2.16 (±1.57) 2.76 (±1.94) 12.42 (±4.01) – –
1-Methylguanosine 1.37 (±0.70) 1.44 (±0.51) 3.35 (±0.49) – –
2-Methylguanosine 0.62 (±0.26) 0.63 (±0.26) 4.52 (±0.86) – –
n number of samples tested
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nine and uridine. It was also confirmed that a higher level of
8-hydroxy-2′-deoxyguanosine could be correlated with oxi-
dative DNA damage, which is also considered to be a
consequence of carcinogenesis.
In another report, the level of 8-hydroxy-2′-deoxyguano-
sine was decreased in cancer patients undergoing surgery and
chemotherapy compared with the baseline [50]. Hence, the
search for the possible tumour markers should not only focus
on nucleoside metabolites but also on deoxynucleosides.
With regard to other cancers, Xu et al. [39] tested if
urinary nucleosides could be used for the diagnosis of
breast cancer. To estimate the origin of the sample, which
may be derived from cancer patients or from healthy
controls, a factor analysis was proposed. It was demon-
strated that the levels of pseudouridine, 1-methyladenosine,
1-methylinosine and 1-methylguanosine were significantly
higher, which should be taken into account in future
research. Moreover, the level of 5-methyluridine was also
much higher in cancer patients than in healthy volunteers,
but the small normal sample did not allow certainty of the
significance of that correlation.
Cho et al. [25] went further and determined the urinary
levels of nucleosides in breast cancer patients before and
after tumour removal. They measured urinary nucleosides
from three groups: (1) healthy individuals, (2) breast cancer
patients awaiting surgery and (3) the same patients
following tumour removal. Pre- and postoperative samples
were collected just before and 2 weeks after surgery and
were directly analysed by column-switching LC/MS/MS
(Fig. 4). The data were statistically assessed using the
Mann–Whitney U test (p<0.05). It was shown that the
levels of nucleosides, such as 1-methyladenosine (p<0.02),
N2,N2-dimethylguanosine (p<0.001), 5-hydroxymethyl-2′-
deoxyuridine (p<0.001) and 8-hydroxy-2′-deoxyguanosine
(p<0.001), were significantly elevated in preoperative
patients compared with normal controls. The levels of the
four modified nucleosides were lower in postsurgery versus
presurgery patients (1-methyladenosine, N2,N2-dimethyl-
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Fig. 2 Principal component analysis of urine nucleoside profiles from
colorectal cancer patients (circles) and healthy controls (crosses).
Asterisks a positions of patients with intestinal villous adenoma, b
positions of 32 responsive cases after surgery, c positions of 11
progressive cases after surgery. PC principal component. (With
permission from [2])
Fig. 3 Mass chromatograms of
nine nucleosides and internal
standard under selected
reaction monitoring operation.
ISTD internal standard.
(With permission from [22])
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guanosine, 5-hydroxymethyl-2′-deoxyuridine and 8-
hydroxy-2′-deoxyguanosine). Furthermore, decreased con-
centrations of the four modified nucleosides after surgery
were observed. In a similar comparison study, postsurgery
concentrations were still higher than in normal controls.
These results are consistent with the report by Xu et al.
[10], in which the same three out of four nucleosides
discussed by Cho et al. [25] were reported as showing
elevated levels (1-methyladenosine, 5-hydroxymethyl-2′-
deoxyuridine and 8-hydroxy-2-deoxyguanosine).
Bullinger et al. [37] proposed different methods. They used
the k nearest neighbour and support vector machine (SVM)
methods within the leave-one-out procedure to predict the
most significant nucleosides in breast cancer patients. They
found elevated concentrations of 1-methylguanosine, 1-
methylinosine, inosine, 3-methyluridine and adenosine.
According to the Battiti–Tesmer algorithm, such nucleosides
as pseudouridine, uridine, inosine, 3-methyluridine were
selected, which suggested some inner redundancy in the
measured nucleoside profiles. A large number (over 200) of
biological samples were assayed and the results were
statistically processed by Frickenschmidt et al. [46]. The
113 urinary samples derived from patients with breast cancer
and 99 control samples from healthy volunteers were studied
using LC/ESI-IT-MS. From each sample, 31 compounds
were statistically analysed using PCA and SVM. PCA
seemed to be inappropriate for such a large data set (212
samples × 31 compounds) because the resulting classification
of the samples was unclear and chaotic. There were no
clusters that should have represented cancer patients and
healthy volunteers, which is usually observed in the analysis
of smaller numbers of samples (fewer than 100). Hence,
Frickenschmidt et al. [46] proposed another statistical model
based on SVM with a recursive feature elimination algorithm.
The sensitivity and specificity of the results were 89.39% and
88.89%, respectively, which is a significant improvement
compared with the widely used breast cancer markers, such
as CA 15–3 (specificity 90–95%, sensitivity 50%). Moreover,
it should be taken into account that both the specificity and
the selectivity of the nucleosides are the most important
factors as regards their role in the diagnosis of cancer.
However, the second equally important aspect is the number
of data in the set on which the analysis is performed: the
higher the analysed number of samples, the more statistically
significant the results and the more credible the role of
nucleosides as cancer markers.
Dieterle et al. [40] classified samples from healthy
individuals and breast cancer patients using two different
Fig. 4 liquid chromatography/
tandem mass spectrometry
chromatograms for urinary
nucleosides from breast cancer
patients before (dotted line)
and after (solid line) surgery.
RT retention time.
(With permission from [25])
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implementations of learning vector quantification (LVQ)
and dynamic LVQ . They also adapted SVM backpropaga-
tions. These three methods were compared in terms of their
sensitivity, specificity and prediction rate. Clinical sensitivity
was calculated as the percentage of true negatives and the
prediction rate was the percentage of true positives and true
negatives in all individuals. As a result, LVQ classified 60 out
of 85 cancer patients and 109 out of 121 healthy patients
correctly. The sensitivity, specificity and prediction rate were
approximated at 70.6%, 90.1% and 82.1%, respectively. The
prediction rate of backpropagation was practically identical to
that of LVQ, with exactly the same specificity and a slightly
higher sensitivity. The prediction rate of SVM was also very
similar to the prediction rate of LVQ, with slightly lower
sensitivity and selectivity. The Wilcoxon test, also applied in
this study, showed no significant differences between the
methods. However, it was recommended to use LVQ for a
further, more extended study.
The artificial neural network (ANN) technique seems to
be a very useful tool in the diagnosis of cancer. In their
study, Seidel et al. [13] used a multilayer perceptron (MLP)
artificial neural network and non-parametric statistical tests,
namely the Kolmogorov–Smirnov test along with the two-
tailed Mann–Whitney test. The samples were collected
from patients suffering from different cancers. The study
groups consisted of 55 patients with histologically docu-
mented malignancies (26 patients with breast cancer, eight
with colorectal cancer, seven with sarcoma, three with
thyroid cancer, three with Hodgkin’s disease, two with
melanoma, two with bronchial carcinoma, two with
gynaecological cancers and two with other malignancies),
13 patients with benign diseases (nine with thyroid
adenoma, two with chondromas, one with lipoma and one
with parathyroid adenoma) and 41 healthy controls. To
compare all the cancer samples with the healthy ones,
Seidel et al. [13] used four input neurons and subsequently
achieved a specificity of 85.4% and a sensitivity of 97%.
Moreover, they distinguished benign from malignant
tumours by MLP with also four input neurons and then
achieved a specificity and sensitivity of 67% and 86%,
respectively. The ANN technique was also used by Yang et
al. [43]. They analysed urine samples (n=69) and serum
samples (n=42) from cancer patients and healthy controls.
Each sample (defined as a pattern) was described by 15
feature variables, which were the concentrations of 15
nucleosides. For the training set, an algorithm called
“gradient descent with momentum and adaptive learning
rate backpropagation” was used. The sensitivity and
specificity calculated for the urine samples were 98% and
94.7%, respectively, and those for the serum samples were
94.7% and 95.8%, respectively. The authors also used the
PCA technique to compare the results with ANN. The PCA
technique appeared to be less sensitive and specific than
ANN. For the urine data set, the sensitivity and the
specificity were 92.2% and 77.8%, respectively, whereas
those for the serum were 73.7% and 79.2%, respectively.
Summary and conclusions
The ongoing development of both analytical techniques and
bioinformatic methods is generating increasing interest in
metabolomics. Nowadays, the application of analytical
techniques is heading towards the reduction of the total
analysis time and implementation of fully automated
systems with the most sensitive analytical detection
methods that enable quantification at a very low concen-
tration of analytes. It is very important to conduct such
research, as so far many peaks obtained in the separation of
biological samples have still not been identified. Certainly
the use of a sensitive and selective method can solve that
problem. Nevertheless, the development level of analytical
procedures so far, although giving complex analytical data,
is still not high enough to estimate the biological value of
nucleosides as cancer markers. Only the use of sensitive
and modern analytical techniques in connection with
bioinformatic methods can facilitate the interpretation of
complex analytical data and therefore make it possible to
highlight the significant role of nucleosides as cancer
biomarkers. To prove the role of nucleosides in carcinogen-
esis, many samples should be determined at an acceptably low
concentration and then statistically evaluated. Basically, the
large data sets obtained from either healthy volunteers or
cancer patients are gathered in databases and can be analysed
further by statistical and chemometric methods. Such data-
bases consist of a variety of information (sex, age, additional
dysfunctions, disease stage along with the analytical results).
Their interpretation without bioinformatic tools can only be
superficial. Eventually, analytical procedures combined with
bioinformatic methods may answer the question about the
actual diagnostic relevance of nucleosides. Given the results
obtained so far, it seems that sooner or later this question will
have a definite answer. To make this a reality, large numbers
of biological samples should be determined and statistically
processed.
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